These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
155 related articles for article (PubMed ID: 17433672)
21. The reversed binding of beta-phenethylamine inhibitors of DPP-IV: X-ray structures and properties of novel fragment and elaborated inhibitors. Nordhoff S; Cerezo-Gálvez S; Feurer A; Hill O; Matassa VG; Metz G; Rummey C; Thiemann M; Edwards PJ Bioorg Med Chem Lett; 2006 Mar; 16(6):1744-8. PubMed ID: 16376544 [TBL] [Abstract][Full Text] [Related]
22. Effect of a single cyclosporine dose on the single-dose pharmacokinetics of sitagliptin (MK-0431), a dipeptidyl peptidase-4 inhibitor, in healthy male subjects. Krishna R; Bergman A; Larson P; Cote J; Lasseter K; Dilzer S; Wang A; Zeng W; Chen L; Wagner J; Herman G J Clin Pharmacol; 2007 Feb; 47(2):165-74. PubMed ID: 17244767 [TBL] [Abstract][Full Text] [Related]
23. Design and synthesis of potent amido- and benzyl-substituted cis-3-amino-4-(2-cyanopyrrolidide)pyrrolidinyl DPP-IV inhibitors. Corbett JW; Dirico K; Song W; Boscoe BP; Doran SD; Boyer D; Qiu X; Ammirati M; Vanvolkenburg MA; McPherson RK; Parker JC; Cox ED Bioorg Med Chem Lett; 2007 Dec; 17(24):6707-13. PubMed ID: 17977724 [TBL] [Abstract][Full Text] [Related]
24. Synthesis, biological evaluation and structural determination of beta-aminoacyl-containing cyclic hydrazine derivatives as dipeptidyl peptidase IV (DPP-IV) inhibitors. Ahn JH; Shin MS; Jun MA; Jung SH; Kang SK; Kim KR; Rhee SD; Kang NS; Kim SY; Sohn SK; Kim SG; Jin MS; Lee JO; Cheon HG; Kim SS Bioorg Med Chem Lett; 2007 May; 17(9):2622-8. PubMed ID: 17331715 [TBL] [Abstract][Full Text] [Related]
25. Design and synthesis of sulfoximine based inhibitors for HIV-1 protease. Raza A; Sham YY; Vince R Bioorg Med Chem Lett; 2008 Oct; 18(20):5406-10. PubMed ID: 18829317 [TBL] [Abstract][Full Text] [Related]
26. Rational design of non-nucleoside, potent, and orally bioavailable adenosine deaminase inhibitors: predicting enzyme conformational change and metabolism. Terasaka T; Tsuji K; Kato T; Nakanishi I; Kinoshita T; Kato Y; Kuno M; Inoue T; Tanaka K; Nakamura K J Med Chem; 2005 Jul; 48(15):4750-3. PubMed ID: 16033254 [TBL] [Abstract][Full Text] [Related]
27. 3-[2-((2S)-2-cyano-pyrrolidin-1-yl)-2-oxo-ethylamino]-3-methyl-butyramide analogues as selective DPP-IV inhibitors for the treatment of type-II diabetes. Coumar MS; Chang CN; Chen CT; Chen X; Chien CH; Tsai TY; Cheng JH; Wu HY; Han CH; Wu SH; Huang YW; Hsu T; Hsu LJ; Chao YS; Hsieh HP; Jiaang WT Bioorg Med Chem Lett; 2007 Mar; 17(5):1274-9. PubMed ID: 17194587 [TBL] [Abstract][Full Text] [Related]
28. [(S)-gamma-(4-Aryl-1-piperazinyl)-l-prolyl]thiazolidines as a novel series of highly potent and long-lasting DPP-IV inhibitors. Yoshida T; Sakashita H; Akahoshi F; Hayashi Y Bioorg Med Chem Lett; 2007 May; 17(9):2618-21. PubMed ID: 17317162 [TBL] [Abstract][Full Text] [Related]
29. Dipeptidyl peptidase-4 inhibitors: clinical data and clinical implications. Ahrén B Diabetes Care; 2007 Jun; 30(6):1344-50. PubMed ID: 17337494 [No Abstract] [Full Text] [Related]
30. 4-arylcyclohexylalanine analogs as potent, selective, and orally active inhibitors of dipeptidyl peptidase IV. Kaelin DE; Smenton AL; Eiermann GJ; He H; Leiting B; Lyons KA; Patel RA; Patel SB; Petrov A; Scapin G; Wu JK; Thornberry NA; Weber AE; Duffy JL Bioorg Med Chem Lett; 2007 Nov; 17(21):5806-11. PubMed ID: 17851076 [TBL] [Abstract][Full Text] [Related]
31. Optimization of 1,4-diazepan-2-one containing dipeptidyl peptidase IV inhibitors for the treatment of type 2 diabetes. Liang GB; Qian X; Feng D; Biftu T; Eiermann G; He H; Leiting B; Lyons K; Petrov A; Sinha-Roy R; Zhang B; Wu J; Zhang X; Thornberry NA; Weber AE Bioorg Med Chem Lett; 2007 Apr; 17(7):1903-7. PubMed ID: 17291750 [TBL] [Abstract][Full Text] [Related]
32. Structure-based design: synthesis and biological evaluation of a series of novel cycloamide-derived HIV-1 protease inhibitors. Ghosh AK; Swanson LM; Cho H; Leshchenko S; Hussain KA; Kay S; Walters DE; Koh Y; Mitsuya H J Med Chem; 2005 May; 48(10):3576-85. PubMed ID: 15887965 [TBL] [Abstract][Full Text] [Related]
33. New treatments for diabetes. Irony I; Parks MH; Meyer RJ N Engl J Med; 2007 May; 356(21):2221; author reply 2222-3. PubMed ID: 17526095 [No Abstract] [Full Text] [Related]
34. New treatments for diabetes. Raz I; Eldor R N Engl J Med; 2007 May; 356(21):2222; author reply 2222-3. PubMed ID: 17526096 [No Abstract] [Full Text] [Related]
35. Design and synthesis of novel HIV-1 protease inhibitors incorporating oxyindoles as the P2'-ligands. Ghosh AK; Schiltz G; Perali RS; Leshchenko S; Kay S; Walters DE; Koh Y; Maeda K; Mitsuya H Bioorg Med Chem Lett; 2006 Apr; 16(7):1869-73. PubMed ID: 16480871 [TBL] [Abstract][Full Text] [Related]
37. Discovery and structure-activity relationships of piperidinone- and piperidine-constrained phenethylamines as novel, potent, and selective dipeptidyl peptidase IV inhibitors. Pei Z; Li X; von Geldern TW; Longenecker K; Pireh D; Stewart KD; Backes BJ; Lai C; Lubben TH; Ballaron SJ; Beno DW; Kempf-Grote AJ; Sham HL; Trevillyan JM J Med Chem; 2007 Apr; 50(8):1983-7. PubMed ID: 17367123 [TBL] [Abstract][Full Text] [Related]
38. Discovery, SAR, and X-ray structure of novel biaryl-based dipeptidyl peptidase IV inhibitors. Qiao L; Baumann CA; Crysler CS; Ninan NS; Abad MC; Spurlino JC; Desjarlais RL; Kervinen J; Neeper MP; Bayoumy SS; Williams R; Deckman IC; Dasgupta M; Reed RL; Huebert ND; Tomczuk BE; Moriarty KJ Bioorg Med Chem Lett; 2006 Jan; 16(1):123-8. PubMed ID: 16236500 [TBL] [Abstract][Full Text] [Related]
39. From the bench to the bedside: dipeptidyl peptidase IV inhibitors, a new class of oral antihyperglycemic agents. Pei Z Curr Opin Drug Discov Devel; 2008 Jul; 11(4):512-32. PubMed ID: 18600568 [TBL] [Abstract][Full Text] [Related]